Analysis of data collected in the European Society for Blood and Marrow Transplantation (EBMT) registry on a cohort of lymphoma patients receiving plerixafor
Plerixafor + granulocyte-colony stimulating factor (G-CSF) is administered to patients with lymphoma who are poor mobilizers of hematopoietic stem cells (HSCs) in Europe. This international, multicenter, non-interventional registry study (NCT01362972) evaluated long-term follow-up of patients with l...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2020
|
| In: |
Bone marrow transplantation
Year: 2019, Jahrgang: 55, Heft: 3, Pages: 613-622 |
| ISSN: | 1476-5365 |
| DOI: | 10.1038/s41409-019-0693-z |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1038/s41409-019-0693-z Verlag, lizenzpflichtig, Volltext: https://www.nature.com/articles/s41409-019-0693-z 
|
| Verfasserangaben: | Anna Sureda, Christian Chabannon, Tamás Masszi, David Pohlreich, Christof Scheid, Catherine Thieblemont, Björn E. Wahlin, Ioanna Sakellarim, Nigel Russell, Andrea Janikova, Anna Dabrowska-Iwanicka, Cyrille Touzeau, Albert Esquirol, Esa Jantunen, Steffie van der Werf, Paul Bosman, Ariane Boumendil, Qianying Liu, Marina Celanovic, Silvia Montoto, Peter Dreger |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1694661822 | ||
| 003 | DE-627 | ||
| 005 | 20220818042118.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200416r20202019xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41409-019-0693-z |2 doi | |
| 035 | |a (DE-627)1694661822 | ||
| 035 | |a (DE-599)KXP1694661822 | ||
| 035 | |a (OCoLC)1341315040 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Sureda, Anna |e VerfasserIn |0 (DE-588)116142993X |0 (DE-627)1024721876 |0 (DE-576)506512037 |4 aut | |
| 245 | 1 | 0 | |a Analysis of data collected in the European Society for Blood and Marrow Transplantation (EBMT) registry on a cohort of lymphoma patients receiving plerixafor |c Anna Sureda, Christian Chabannon, Tamás Masszi, David Pohlreich, Christof Scheid, Catherine Thieblemont, Björn E. Wahlin, Ioanna Sakellarim, Nigel Russell, Andrea Janikova, Anna Dabrowska-Iwanicka, Cyrille Touzeau, Albert Esquirol, Esa Jantunen, Steffie van der Werf, Paul Bosman, Ariane Boumendil, Qianying Liu, Marina Celanovic, Silvia Montoto, Peter Dreger |
| 264 | 1 | |c 2020 | |
| 300 | |a 10 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Published online: 30 September 2019 | ||
| 500 | |a Gesehen am 16.04.2020 | ||
| 520 | |a Plerixafor + granulocyte-colony stimulating factor (G-CSF) is administered to patients with lymphoma who are poor mobilizers of hematopoietic stem cells (HSCs) in Europe. This international, multicenter, non-interventional registry study (NCT01362972) evaluated long-term follow-up of patients with lymphoma who received plerixafor for HSC mobilization versus other mobilization methods. Propensity score matching was conducted to balance baseline characteristics between comparison groups. The following mobilization regimens were compared: G-CSF + plerixafor (G + P) versus G-CSF alone; G + P versus G-CSF + chemotherapy (G + C); and G-CSF + plerixafor + chemotherapy (G + P + C) versus G + C. The primary outcomes were progression-free survival (PFS), overall survival (OS), and cumulative incidence of relapse (CIR). Overall, 313/3749 (8.3%) eligible patients were mobilized with plerixafor-containing regimens. After propensity score matching, 70 versus 36 patients were matched in the G + P versus G-CSF alone cohort, 124 versus 124 in the G + P versus G + C cohort, and 130 versus 130 in the G + P + C versus G + C cohort. For both PFS and OS, the upper bound of confidence interval for the hazard ratio was >1.3 for all comparisons, implying that non-inferiority was not demonstrated. No major differences in PFS, OS, and CIR were observed between the plerixafor and comparison groups. | ||
| 534 | |c 2019 | ||
| 700 | 1 | |a Dreger, Peter |e VerfasserIn |0 (DE-588)1028891881 |0 (DE-627)732699894 |0 (DE-576)376320966 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Bone marrow transplantation |d London : Springer Nature, 1997 |g 55(2020), 3, Seite 613-622 |h Online-Ressource |w (DE-627)320433366 |w (DE-600)2004030-1 |w (DE-576)091012996 |x 1476-5365 |7 nnas |a Analysis of data collected in the European Society for Blood and Marrow Transplantation (EBMT) registry on a cohort of lymphoma patients receiving plerixafor |
| 773 | 1 | 8 | |g volume:55 |g year:2020 |g number:3 |g pages:613-622 |g extent:10 |a Analysis of data collected in the European Society for Blood and Marrow Transplantation (EBMT) registry on a cohort of lymphoma patients receiving plerixafor |
| 856 | 4 | 0 | |u https://doi.org/10.1038/s41409-019-0693-z |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.nature.com/articles/s41409-019-0693-z |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20200416 | ||
| 993 | |a Article | ||
| 994 | |a 2020 | ||
| 998 | |g 1028891881 |a Dreger, Peter |m 1028891881:Dreger, Peter |d 910000 |d 910100 |e 910000PD1028891881 |e 910100PD1028891881 |k 0/910000/ |k 1/910000/910100/ |p 21 |y j | ||
| 999 | |a KXP-PPN1694661822 |e 3624019066 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"recId":"1694661822","name":{"displayForm":["Anna Sureda, Christian Chabannon, Tamás Masszi, David Pohlreich, Christof Scheid, Catherine Thieblemont, Björn E. Wahlin, Ioanna Sakellarim, Nigel Russell, Andrea Janikova, Anna Dabrowska-Iwanicka, Cyrille Touzeau, Albert Esquirol, Esa Jantunen, Steffie van der Werf, Paul Bosman, Ariane Boumendil, Qianying Liu, Marina Celanovic, Silvia Montoto, Peter Dreger"]},"physDesc":[{"extent":"10 S."}],"note":["Published online: 30 September 2019","Gesehen am 16.04.2020"],"person":[{"role":"aut","family":"Sureda","given":"Anna","display":"Sureda, Anna"},{"given":"Peter","display":"Dreger, Peter","role":"aut","family":"Dreger"}],"id":{"eki":["1694661822"],"doi":["10.1038/s41409-019-0693-z"]},"title":[{"title_sort":"Analysis of data collected in the European Society for Blood and Marrow Transplantation (EBMT) registry on a cohort of lymphoma patients receiving plerixafor","title":"Analysis of data collected in the European Society for Blood and Marrow Transplantation (EBMT) registry on a cohort of lymphoma patients receiving plerixafor"}],"origin":[{"dateIssuedDisp":"2020","dateIssuedKey":"2020"}],"language":["eng"],"relHost":[{"pubHistory":["Nachgewiesen 19.1997 -"],"language":["eng"],"part":{"text":"55(2020), 3, Seite 613-622","extent":"10","issue":"3","year":"2020","pages":"613-622","volume":"55"},"type":{"bibl":"periodical","media":"Online-Ressource"},"physDesc":[{"extent":"Online-Ressource"}],"recId":"320433366","title":[{"title":"Bone marrow transplantation","title_sort":"Bone marrow transplantation"}],"note":["Gesehen am 17.01.25"],"id":{"zdb":["2004030-1"],"eki":["320433366"],"issn":["1476-5365"]},"origin":[{"publisherPlace":"London ; Basingstoke ; London","dateIssuedDisp":"1997-","dateIssuedKey":"1997","publisher":"Springer Nature ; Macmillan ; Nature Publishing Group"}],"disp":"Analysis of data collected in the European Society for Blood and Marrow Transplantation (EBMT) registry on a cohort of lymphoma patients receiving plerixaforBone marrow transplantation"}],"type":{"media":"Online-Ressource","bibl":"article-journal"}} | ||
| SRT | |a SUREDAANNAANALYSISOF2020 | ||